Sucampo Pharmaceuticals — Q3 2015 Earnings Presentation
25 slides from Sucampo Pharmaceuticals's earnings presentation, Nov 4, 2015
Slide 1: Q3 2015 Financial Results and Corporate Update
eo $ sucamPo Q3 2015 Financial Results and Corporate Update November 4, 2015
Slide 2: Introductions and Forward-Looking Statements
Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs
Slide 3: Agenda
Agenda $ sucampo_ Pipeline Update Peter Kiener, D. Phil Closing Remarks Peter Greenleaf
Slide 4: Forward Looking Statement
Forward Looking Statement $ sucampo_ This presentation contains "forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results t
Slide 5: Q3 2015 - Peter Greenleaf, CEO
Q3 2015 Corporate Update Peter Greenleaf, CEO
Slide 6: Strong Financial and Corporate Results
Strong Financial and Corporate Results $ SUCAMPO. * Triple-digit growth in our GAAP earnings * Strong performance of flagship brand, AMITIZA® (lubiprostone) in the U.S. and Japan + Successfully completed tender offer for R-Tech Ueno (RTU) * Continued execution against strategic plan set forth last y
Slide 7: Strong Financial Performance
Strong Financial Performance * 6% overall revenue growth - 16% excluding one-time Q3 2014 milestone — 15% U.S. AMITIZA royalty revenue growth — 20% product sales revenue growth, excluding one-time Q3 2014 milestone + 389% increase in net income to $7.2M * 433% increase in EPS to $0.16
Slide 8: U.S. AMITIZA Performance
U.S. AMITIZA Performance * Takeda AMITIZA net sales for royalty calc. purposes — Grew 15% YoY to $101.7M — Continued volume growth — AMITIZA growth outpaces total market growth + AMITIZA prescriptions — ~379,000 TRx, increased 10.4% YoY + Market grew 6% — ~127,000 TRx’s in September + Second highest
Slide 9: Japan AMITIZA Performance
Japan AMITIZA Performance « Sucampo revenue - Sales increased 15.5% to $10.3M + Volume-driven growth + Mylan remains committed to AMITIZA — Significant detailing efforts — AMITIZA still the only prescription medication approved for CC
Slide 10: 2015 Guidance
2015 Guidance $ sucampo + Net income: $30-$35M + EPS: $0.65-$0.75 + Adjusted EBITDA: $55-60M
Slide 11: AMITIZA Globally
AMITIZA Globally + North America - Health Canada approved NDA for AMITIZA for CIC in adults * Takeda plans to launch 1H16 + Europe — Spain has issued National Marketing Authorization’s for AMITIZA for CIC + Rest of World — Russia, Mexico and South Korea to begin P3 studies for CIC in 1H16 + Clinical
Slide 12: Acquisition of R-Tech Ueno
Acquisition of R-Tech Ueno Immediately accretive and diversifies our pipeline + Strategic benefits: — Increased revenues, enhanced profitability and stronger cash flow generation — Control over AMITIZA manufacturing and supply chain - Several product candidates across multiple disease areas * Tender
Slide 13: FY 2016 Guidance
FY 2016* Guidance $ sucampo + Net income: $45-50M + EPS: $0.97-$1.07 + Adjusted EBITDA: $100-$105M** « Expect to achieve $11.4M in synergies + Revenue: $195-$205M “Excluding non-cash, projected amortization of intangibles and any purchase accounting entries related tothe acquisition “Net income befo
Slide 14: Pipeline Update
Pipeline Update Peter Kiener, D.Phil, CSO
Slide 15: Lifecycle Management Programs for AMITIZA
Lifecycle Management Programs for AMITIZA * Pediatric Functional Constipation (6-17 years) — Program using the current formulation — Expect data in 2H16 — Regulatory submission for end of 2016 + Alternate Formulation — Initiate P3 study in adult patients with CIC in 2H16 — Success in adults with alt
Slide 16: Cobiprostone
Cobiprostone + NERD/sGERD — P2 trial continues on-schedule — Enroll last patient this month — Expect to announce top-line data in 1H16 + Oral Mucositis — Initiated P2a trial in Sept. 2015 — Expect to announce top-line data in 1H17 — Granted Fast Track Designation by U.S. FDA
Slide 17: R-Tech Ueno Pipeline
R-Tech Ueno Pipeline VAP-1 inhibitors — Enzyme and adhesion receptor - Potential indications including NASH, COPD, diabetic macular edema and diabetic retinopathy and modulation of tumor-specific immune responses. + RTU-1096 — Next step: generate additional preclinical data + RTU-009 — Next step: co
Slide 18: Financial Update
Financial Update Andrew Smith, CFO
Slide 19: Significant Non-GAAP Earnings Growth
Significant Non-GAAP Earnings Growth $ sucampo_ fe... $10.0 Q3-14 Q3-15 EBITDAS
Slide 20: Expense Highlights
Expense Highlights $ sucaMPo_ Q3-14 Q3-15 Q3-14 Q3-15 Q3-14 Q3-15 Q3-14 Q3-15 Cost of Goods Sold R&D Expenses G&A Expenses S&M Expenses In millions of USD 20
Slide 21: Effective Tax Rate
Effective Tax Rate $ sucaMPo_ 61% 37% Q3-14 — Q3-15.
Slide 22: Strong Balance Sheet
Strong Balance Sheet $ sucampo_ | item ‘| As of 10/20/15 | As of 09/30/15 As of 12/31/14 Cash, Cash $135.0M $136.6M $26.6M $110.0M Equivalents, Restricted Cash and Investments Notes Payable ($250.0M) ($21.7M) $4.1M ($25.8M) | _item | Asof oasis | increase | As of 09/30/14 Cash Flow from $24.2M $16.7
Slide 23: Closing Remarks
Closing Remarks Peter Greenleaf, CEO
Slide 24: Focus on Strong 2015 Close
Focus on Strong 2015 Close $ sucampo * Continue to deliver outstanding financial performance driven by top and bottom line growth « Successfully integrate RTU, deliver on our financial targets, and make key decisions about the pipeline programs we gain through this acquisition * Continue to advance
Slide 25: Q&A
Q&A
Sucampo Pharmaceuticals — Q3 2015 Earnings Presentation on 6ix